Analyst Whitney Ijem from Canaccord Genuity maintained a Buy rating on Tenaya Therapeutics (TNYA – Research Report) and decreased the price target to $6.00 from $18.00.
Meet Samuel – Your Personal Investing Prophet
- Start a conversation with TipRanks’ trusted, data-backed investment intelligence
- Ask Samuel about stocks, your portfolio, or the market and get instant, personalized insights in seconds
Whitney Ijem’s rating is based on several key factors. Firstly, the positive clinical data from Tenaya Therapeutics’ TN-201 program for MYBPC3-associated hypertrophic cardiomyopathy (HCM) has shown promising results. The initial data from the first cohort of the Phase 1b/2 trial indicated a clear impact of the treatment on protein creation and disease progression, which is encouraging for future developments.
Additionally, Tenaya’s financial position has been strengthened by a recent public offering, providing a cash runway into mid-2026. This financial stability, combined with the progress in their gene therapy programs, supports the potential for future commercialization of their treatments. Despite a reduction in the price target from $18 to $6, the advancements in clinical trials and financial health underpin the Buy rating.
In another report released on March 11, Chardan Capital also maintained a Buy rating on the stock with a $9.00 price target.
TNYA’s price has also changed dramatically for the past six months – from $2.060 to $0.600, which is a -70.87% drop .